Demographic and clinical characteristics of patients with HCC

*Results in the table refer to the following analyses: 1) original analysis; 2) Inclusion of patients with polyps detected and removed at (procto-) sigmoidoscopy; 3) Single inclusion of individuals in the cohort of their first colonoscopy with polypectomy between 1998 and 2003; 4) Limiting the definition of a surveillance event to a colonoscopy; 5) Including people from the SEER-Medicare data with a cancer diagnosis.Probability of first surveillance event and first polypectomy event within 5 years after baseline colonoscopy with polypectomy among Medicare beneficiaries, stratified by cohort based on date of baseline colonoscopy with polypectomy – results of sensitivity analyses (estimated using the Kaplan-Meier method).

Descriptive characteristics of 3957 patients of study population within the Surveillance, Epidemiology, and End Results (SEER) Medicare-linked database and 272 propensity score-matched patients.

Table 1: List of drugs used to treat acute myeloid leukemia.

Table 2: List of supportive care drugs.

Table 3: List of transplant drugs.*

Table 4: Transplant codes.

Patients’ characteristics by sodium-glucose cotransporter 2 (SGLT2) inhibitor use status among 3,185 hepatocellular carcinoma patientsb'*'.

The effect of radiation therapy on subsequent myeloid neoplasms after breast cancer according to data source (N = 60,426).

Associations between sodium-glucose cotransporter 2 (SGLT2) inhibitor use and mortality among hepatocellular carcinoma patients with T2DMb'*'.